Vaxcyte Inc's Comment on Sales, Marketing and Customers
On October 13, 2023, the company entered into a Commercial Manufacturing and Supply Agreement with Lonza. Under this agreement, Lonza will build and operate a dedicated manufacturing suite at its Visp, Switzerland facility to produce key components, including drug substances, for the company's proprietary PCV franchise and other products or intermediates. Lonza will act as a preferred, non-exclusive supplier, while the company retains the right to engage alternate or backup manufacturers. The agreement includes provisions for capital expenditure contributions, monthly service fees, suite fees, service fees based on employee costs, and other pass-through costs. The agreement is effective until December 31, 2038, with options for renewal and termination under specified conditions.
In a significant advancement for public health, Vaxcyte has announced encouraging topline data from its Phase 1/2 clinical study of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate designed for adults aged 50 and older. The data reveal that VAX-31 elicits strong opsonophagocytic activity (OPA) immune responses across all 31 serotypes tested, showcasing its potential to enhance protection against pneumococcal disease in older populations an age group particularly vulnerable to severe infections.The study aimed to evaluate the safety, tolerability, and immunogenicity of VAX-31 in older adults, a demographic at heightened risk of pneumococcal pneumonia, bacteremia, and meningitis. With the backdrop ...
Vaxcyte, a leading biotechnology company focused on developing next-generation vaccines, recently announced the completion of enrollment for its Phase 1/2 study evaluating VAX-31 as a potential preventive measure for Invasive Pneumococcal Disease (IPD) in adults aged 50 and older. This milestone brings the company closer to its goal of addressing a significant public health concern and potentially improving the lives of millions.Pneumococcal disease is caused by the bacteria Streptococcus pneumoniae, which can cause severe infections such as pneumonia, meningitis, and bacteremia. While children and individuals with weakened immune systems are at higher risk, adults aged 50 and older also face a substantial b...
Vaxcyte Makes Significant Progress in the Development of a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) FranchiseVaxcyte, a leading biotechnology company, has recently announced important updates regarding their ongoing clinical and regulatory advancements in the development of a potential best-in-class Pneumococcal Conjugate Vaccine (PCV) franchise. With the primary goal of combating pneumococcal diseases, Vaxcyte has made substantial strides in its research, including the initiation of phase 2 trials and successful discussions with the FDA for a phase 3 pivotal study.In their recent press release, Vaxcyte revealed that they have successfully dosed the first participants in the phase 2 porti...
In the latest development of its ambitious long-term strategy, Vaxcyte has exercised its option to obtain exclusive manufacturing and development rights through a crucial agreement with Sutro Biopharma. This move is set to have a significant impact on the company as it solidifies control over the production and advancement of key components for its Pneumococcal Conjugate Vaccine (PCV) franchise. The agreement between Vaxcyte and Sutro Biopharma grants Vaxcyte independent development and manufacturing rights for the cell-free extract, a vital component of the PCV vaccine candidates. This decision marks a watershed moment for the company, offering enhanced control and autonomy over important aspects o...
Vaxcyte Inc’s Comment on Sales, Marketing and Customers
On October 13, 2023, the company entered into a Commercial Manufacturing and Supply Agreement with Lonza. Under this agreement, Lonza will build and operate a dedicated manufacturing suite at its Visp, Switzerland facility to produce key components, including drug substances, for the company's proprietary PCV franchise and other products or intermediates. Lonza will act as a preferred, non-exclusive supplier, while the company retains the right to engage alternate or backup manufacturers. The agreement includes provisions for capital expenditure contributions, monthly service fees, suite fees, service fees based on employee costs, and other pass-through costs. The agreement is effective until December 31, 2038, with options for renewal and termination under specified conditions.
Sources:
Vaxcyte Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Vaxcyte Inc’s corporate clients.
For your research, we’ve provided 9 tables on Vaxcyte Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
